SCHEMBL14634941

SCHEMBL14634941

Cc1cc(Nc2ncc(-c3[nH]nc(C)c3C)c(N)n2)cc(S(C)(=O)=O)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
SYK P43405 1/20 0.35
IGF1R P08069 1/20 0.34
JAK1 P23458 3/20 0.34
JAK3 P52333 2/20 0.34
RIPK2 O43353 1/20 0.33
NOD2 Q9HC29 1/20 0.33
PTGS2 P35354 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
MAP4K1 Q92918 1/20 0.33
JAK2 O60674 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3C2G O75747 1/20 0.33
PIK3CG P48736 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634398 0.88 JAK1 (0.47) JAK1JAK3RIPK2NOD2CCNT1
SCHEMBL14634826 0.82 JAK3 (0.38) RAB9ASYKJAK1JAK3CDK2
SCHEMBL14634814 0.80 GRM4 (0.43) SYKJAK1JAK3CCNT1CDK2
SCHEMBL14633978 0.77 EPHB4 (0.41) SYKJAK1JAK3PTGS2CCNT1
SCHEMBL14633684 0.77 ITK (0.37) JAK1JAK3RIPK2NOD2PTGS2
SCHEMBL14634889 0.77 KDR (0.55) SYKIGF1RJAK1JAK3CDK2
SCHEMBL2468102 0.77 CDK2 (0.39) NPC1TSHRRAB9ASMN1; SMN2SYK
SCHEMBL2471505 0.75 RIPK2 (0.42) SYKRIPK2PTGS2CCNT1CCNE1
SCHEMBL14634487 0.75 IKBKB (0.38) IGF1RJAK1JAK3RIPK2PTGS2
SCHEMBL2467170 0.75 CDK2 (0.39) SYKJAK1JAK3PTGS2CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 NPC1 3580/4885TSHR 681/4885RAB9A 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.